OBJECTIVE: Identification of low-frequency variants is of clinical importance in the identification of preexisting drug resistance. Using 'ultra-deep' sequencing, we address the detection of potential resistance to the chemokine (C-C motif) receptor 5 (CCR5) antagonist, maraviroc, due to the pretreatment presence of low levels of chemokine (CXC motif) receptor 4 (CXCR4)-using virus. METHODS: We present a novel protocol for the phenotyping of HIV based on '454' pyrosequence data and apply this to two large data sets comprised of 104 628 (before treatment, day 1) and 191 637 (after treatment, day 11) reads from the envelope region. We study resistance in the context of the evolutionary history of the intrapatient viral population. Variation was also investigated both within and outside the V3 region, the region associated with the receptor switch. RESULTS: CXCR4-using virus can be detected at low frequency prior to maraviroc treatment ( approximately 0.5%) and at high frequency after failure of monotherapy ( approximately 81%). Inferring an evolutionary tree from the 1674 unique reads that span the V3 region confirms that the CXCR4-using population emerged from low-frequency CXCR4-using variants present before treatment. Changes in the frequency of amino acid residues used at individual sites were found in regions outside the V3 region, indicative of other potential sites associated with receptor usage. CONCLUSION: We have provided a high-resolution snapshot of intrapatient viral variation, prior and after treatment with maraviroc, and detected preexisting CXCR4-using variants present at an extremely low frequency. The evolutionary analysis demonstrates the extent of diversity present at a single time point within an infected individual and the rapid effect of drug pressure on the structure of a viral population.
OBJECTIVE: Identification of low-frequency variants is of clinical importance in the identification of preexisting drug resistance. Using 'ultra-deep' sequencing, we address the detection of potential resistance to the chemokine (C-C motif) receptor 5 (CCR5) antagonist, maraviroc, due to the pretreatment presence of low levels of chemokine (CXC motif) receptor 4 (CXCR4)-using virus. METHODS: We present a novel protocol for the phenotyping of HIV based on '454' pyrosequence data and apply this to two large data sets comprised of 104 628 (before treatment, day 1) and 191 637 (after treatment, day 11) reads from the envelope region. We study resistance in the context of the evolutionary history of the intrapatient viral population. Variation was also investigated both within and outside the V3 region, the region associated with the receptor switch. RESULTS: CXCR4-using virus can be detected at low frequency prior to maraviroc treatment ( approximately 0.5%) and at high frequency after failure of monotherapy ( approximately 81%). Inferring an evolutionary tree from the 1674 unique reads that span the V3 region confirms that the CXCR4-using population emerged from low-frequency CXCR4-using variants present before treatment. Changes in the frequency of amino acid residues used at individual sites were found in regions outside the V3 region, indicative of other potential sites associated with receptor usage. CONCLUSION: We have provided a high-resolution snapshot of intrapatient viral variation, prior and after treatment with maraviroc, and detected preexisting CXCR4-using variants present at an extremely low frequency. The evolutionary analysis demonstrates the extent of diversity present at a single time point within an infected individual and the rapid effect of drug pressure on the structure of a viral population.
Authors: David C Nickle; Mark A Jensen; Geoffrey S Gottlieb; Daniel Shriner; Gerald H Learn; Allen G Rodrigo; James I Mullins Journal: Science Date: 2003-03-07 Impact factor: 47.728
Authors: Jeannette M Whitcomb; Wei Huang; Signe Fransen; Kay Limoli; Jonathan Toma; Terri Wrin; Colombe Chappey; Linda D B Kiss; Ellen E Paxinos; Christos J Petropoulos Journal: Antimicrob Agents Chemother Date: 2006-11-20 Impact factor: 5.191
Authors: William Brockman; Pablo Alvarez; Sarah Young; Manuel Garber; Georgia Giannoukos; William L Lee; Carsten Russ; Eric S Lander; Chad Nusbaum; David B Jaffe Journal: Genome Res Date: 2008-01-22 Impact factor: 9.043
Authors: M Koot; R van Leeuwen; R E de Goede; I P Keet; S Danner; J K Eeftinck Schattenkerk; P Reiss; M Tersmette; J M Lange; H Schuitemaker Journal: J Infect Dis Date: 1999-01 Impact factor: 5.226
Authors: Christian Gabriel; Stephanie Stabentheiner; Martin Danzer; Johannes Pröll Journal: Transfus Med Hemother Date: 2011-09-25 Impact factor: 3.747
Authors: Luke C Swenson; Theresa Mo; Winnie W Y Dong; Xiaoyin Zhong; Conan K Woods; Mark A Jensen; Alexander Thielen; Douglass Chapman; Marilyn Lewis; Ian James; Jayvant Heera; Hernan Valdez; P Richard Harrigan Journal: J Infect Dis Date: 2011-01-15 Impact factor: 5.226
Authors: Jonathan J Juliano; Kimberly Porter; Victor Mwapasa; Rithy Sem; William O Rogers; Frédéric Ariey; Chansuda Wongsrichanalai; Andrew Read; Steven R Meshnick Journal: Proc Natl Acad Sci U S A Date: 2010-11-01 Impact factor: 11.205
Authors: Sherry McLaughlin; Luke C Swenson; Shengbo Hu; Paul Hughes; P Richard Harrigan; Robert W Coombs; Lisa M Frenkel Journal: AIDS Res Hum Retroviruses Date: 2013-03-06 Impact factor: 2.205
Authors: Stephanie M Willerth; Hélder A M Pedro; Lior Pachter; Laurent M Humeau; Adam P Arkin; David V Schaffer Journal: PLoS One Date: 2010-10-22 Impact factor: 3.240
Authors: Jan Weber; Ana C Vazquez; Dane Winner; Richard M Gibson; Ariel M Rhea; Justine D Rose; Doug Wylie; Kenneth Henry; Alison Wright; Kevin King; John Archer; Eva Poveda; Vicente Soriano; David L Robertson; Paul D Olivo; Eric J Arts; Miguel E Quiñones-Mateu Journal: J Clin Microbiol Date: 2013-03-13 Impact factor: 5.948